amphetamine has been researched along with Motion Sickness in 18 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Motion Sickness: Disorder caused by motion. It includes sea sickness, train sickness, roller coaster rides, rocking chair, hammock swing, car sickness, air sickness, or SPACE MOTION SICKNESS. Symptoms include nausea, vomiting and/or dizziness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The fact that amphetamine, a noradrenaline releaser, prevents motion sickness leads the hypothesis of Wood and Graybiel that the noradrenergic neuron system in the brain stem acts against the development of motion sickness." | 7.68 | Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness. ( Matsunaga, T; Morita, M; Takeda, N; Wada, H; Yamatodani, A, 1990) |
| "The major conclusions of this review are: 1) that selective enhancement of dopaminergic transmission, not noradrenergic, is sufficient to account for amphetamine-induced resistance and perhaps natural resistance to motion sickness; 2) the site of this enhanced dopaminergic transmission is probably within the basal ganglia; and 3) the neuropharmacology of the basal ganglia, but not the brainstem vestibular areas, can account for the therapeutic synergism of scopolamine and amphetamine." | 4.77 | Mechanisms underlying the antimotion sickness effects of psychostimulants. ( Kohl, RL; Lewis, MR, 1987) |
| "The present review has extended the general theory of motion sickness proposed by Wood and Graybiel [135, 136] by identifying specific neurophysiological mechanisms that are involved in motion sickness and by interpreting the actions of both scopolamine and amphetamine as effective anti-motion sickness drugs within this neurophysiological context." | 4.76 | Motion sickness: a modulatory role for the central cholinergic nervous system. ( Homick, JL; Kohl, RL, 1983) |
| "The fact that amphetamine, a noradrenaline releaser, prevents motion sickness leads the hypothesis of Wood and Graybiel that the noradrenergic neuron system in the brain stem acts against the development of motion sickness." | 3.68 | Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness. ( Matsunaga, T; Morita, M; Takeda, N; Wada, H; Yamatodani, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (83.33) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| ARNER, O | 1 |
| DIAMANT, H | 1 |
| LEITE, CC | 1 |
| MONNIER, AJ | 1 |
| MAUREL, EF | 1 |
| Kohl, RL | 4 |
| Homick, JL | 1 |
| Sandoz, GR | 1 |
| Reschke, MF | 1 |
| Calkins, DS | 1 |
| Richelson, E | 1 |
| Graybiel, A | 4 |
| Wood, CD | 4 |
| Knepton, J | 1 |
| Hoche, JP | 1 |
| Perkins, GF | 1 |
| Takeda, N | 1 |
| Morita, M | 1 |
| Yamatodani, A | 1 |
| Wada, H | 1 |
| Matsunaga, T | 1 |
| Lewis, MR | 1 |
| Petrin, A | 1 |
| Roberts, VL | 1 |
| Aston, R | 1 |
| Ferrotti, A | 1 |
| Naess, K | 1 |
| Johnson, WH | 1 |
| Kennedy, RE | 1 |
| McDonough, RB | 1 |
3 reviews available for amphetamine and Motion Sickness
| Article | Year |
|---|---|
Motion sickness: a modulatory role for the central cholinergic nervous system.
Topics: Acetylcholine; Afferent Pathways; Amphetamine; Animals; Cholinergic Fibers; Efferent Pathways; Hair | 1983 |
Mechanisms underlying the antimotion sickness effects of psychostimulants.
Topics: Amphetamine; Basal Ganglia; Dopamine; Humans; Motion Sickness; Psychotropic Drugs; Scopolamine; Vest | 1987 |
[Motion sickness and its treatment (author's transl)].
Topics: Amphetamine; Drug Combinations; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Motion | 1974 |
4 trials available for amphetamine and Motion Sickness
| Article | Year |
|---|---|
Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine.
Topics: Adaptation, Physiological; Adult; Amphetamine; Double-Blind Method; Doxepin; Drug Therapy, Combinati | 1993 |
Human assay of antimotion sickness drugs.
Topics: Adult; Amphetamine; Clinical Trials as Topic; Dimenhydrinate; Dose-Response Relationship, Drug; Drug | 1975 |
Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions.
Topics: Adolescent; Adult; Amphetamine; Antiemetics; Benzamides; Chlorpromazine; Clinical Trials as Topic; C | 1968 |
Side effects of some antimotion sickness drugs as measured by psychomotor test and questionnaires.
Topics: Amphetamine; Benzamides; Chlorpromazine; Humans; Male; Meclizine; Motion Sickness; Placebos; Psychol | 1966 |
11 other studies available for amphetamine and Motion Sickness
| Article | Year |
|---|---|
[Antihistamine-amphetamine therapy of motion sickness].
Topics: Amphetamine; Amphetamines; Anti-Allergic Agents; Histamine H1 Antagonists; Humans; Motion Sickness | 1954 |
[A new therapy for seasickness; successful clinical trial].
Topics: Amphetamine; Amphetamines; Belladonna Alkaloids; Motion Sickness; Phenobarbital | 1958 |
[New treatment of confirmed seasickness; therapeutic results].
Topics: Amphetamine; Amphetamines; Atropa belladonna; Humans; Motion Sickness; Muscarinic Antagonists; Paras | 1955 |
[Treatment of motion sickness by a new medicinal combination].
Topics: Amphetamine; Amphetamines; Atropa belladonna; Humans; Motion Sickness; Muscarinic Antagonists; Paras | 1955 |
Autonomic function and plasma catecholamines following stressful sensory stimuli.
Topics: Adolescent; Adult; Aerospace Medicine; Amphetamine; Autonomic Nervous System; Dexamethasone; Disease | 1993 |
Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Brain Stem; Disease Models, Animal; Homovanill | 1990 |
Quantitative aspects of vibration-induced mortality.
Topics: Amphetamine; Animals; Atropine; Chlordiazepoxide; Dextroamphetamine; Epinephrine; Hexamethonium Comp | 1969 |
[Therapeutic considerations on kinetoses].
Topics: Acceleration; Aerospace Medicine; Amphetamine; Barbiturates; Histamine H1 Antagonists; Humans; Motio | 1970 |
Theory of antimotion sickness drug mechanisms.
Topics: Adult; Amphetamine; Drug Synergism; Histamine H1 Antagonists; Humans; Male; Motion Sickness; Phenoth | 1972 |
[Motion sickness].
Topics: Amphetamine; Humans; Motion Sickness; Promethazine; Scopolamine | 1971 |
Some otological problems during space flight.
Topics: Amphetamine; Cyclizine; Ear, Inner; Ephedrine; Humans; Illusions; Motion Sickness; Scopolamine; Spac | 1971 |